scholarly journals Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?

2017 ◽  
Vol 65 (suppl_2) ◽  
pp. S89-S99 ◽  
Author(s):  
Joy E Lawn ◽  
Fiorella Bianchi-Jassir ◽  
Neal J Russell ◽  
Maya Kohli-Lynch ◽  
Cally J Tann ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Group B

scholarly journals Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

2017 ◽  
Vol 65 (suppl_2) ◽  
pp. S200-S219 ◽  
Author(s):  
Anna C Seale ◽  
Fiorella Bianchi-Jassir ◽  
Neal J Russell ◽  
Maya Kohli-Lynch ◽  
Cally J Tann ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Group B

scholarly journals Prevention of neonatal group B streptococcal sepsis in Hungary in 2012. Preliminary data of a nation-wide survey

2014 ◽  
Vol 155 (29) ◽  
pp. 1167-1172
Author(s):  
István Sziller ◽  
Miklós Szabó ◽  
Andrea Valek ◽  
Barbara Rigó ◽  
Nándor Ács
Keyword(s):  
Public Health ◽  
Pregnant Women ◽  
Early Onset ◽  
Obstetric Care ◽  
International Standards ◽  
Preventive Strategy ◽  
Streptococcal Disease ◽  
Neonatal Group ◽  
Group B Streptococcal Disease ◽  
Group B

Introduction: At present, there is no obligatory guideline for the prevention of early-onset neonatal group B streptococcal disease in Hungary. Aim: The aim of the present study was to gain insight into the spontaneously developed preventive strategy of the domestic obstetric divisions and departments in Hungary. Method: Standardized questionnaire was sent out to each of the 71 obstetric divisions and departments in Hungary. Results: Overall, 20 (27.4%) of the chairpersons replied, and thus, 39.9% of the total number of live births in Hungary were included in the study. Despite missing public health guidelines, each of the divisions and departments developed their own strategy to prevent neonatal group B streptococcal disease. In 95% of cases, bacterial culture of the lower vagina was the method of identifying pregnant women at risk. In 5% of the cases intrapartum antibiotic prophylaxis was based on risk assessment only. Of the departments using culture-based prophylaxis, 58% departments sampled women after completion of 36th gestational weeks. Antibiotic of choice was penicillin or ampicillin in 100% of cases. Of the study participants, 80% reported on multiple administration of colonized pregnant women after onset of labor or rupture of the membranes. Conclusions: The authors concluded that the rate of participation in the study was low. However, prevention of early-onset neonatal group B streptococcal infection is a priority of obstetric care in Hungary. Lack of a nation-wide public health policy did not prevent obstetric institutions in this country to develop their own prevention strategy. In the majority of cases and institutions, the policy is consistent with the widely accepted international standards. Orv. Hetil., 2014, 155(29), 1167–1172.

scholarly journals Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study

2019 ◽  
Vol 23 (67) ◽  
pp. 1-40 ◽  
Author(s):  
Clara Carreras-Abad ◽  
Madeleine Cochet ◽  
Tom Hall ◽  
Laxmee Ramkhelawon ◽  
Asma Khalil ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Feasibility Study ◽  
Group B Streptococcus ◽  
Serotype Distribution ◽  
Invasive Group ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Intrapartum Antibiotic ◽  
Group B ◽  
Operational Aspects

Background Group B streptococcus is the leading cause of infection in infants. Currently, intrapartum antibiotic prophylaxis is the major strategy to prevent invasive group B streptococcus disease. However, intrapartum antibiotic prophylaxis does not prevent maternal sepsis, premature births, stillbirths or late-onset disease. Maternal vaccination may offer an alternative strategy. Multivalent polysaccharide protein conjugate vaccine development is under way and a serocorrelate of protection is needed to expedite vaccine licensure. Objectives The ultimate aim of this work is to determine the correlate of protection against the major group B streptococcus disease-causing serotypes in infants in the UK. The aim of this feasibility study is to test key operational aspects of the study design. Design Prospective cohort study of pregnant women and their infants in a 6-month period (1 July to 31 December 2018). Setting Five secondary and tertiary hospitals from London and South England. National iGBS disease surveillance was conducted in all trusts in England and Wales. Participants Pregnant women aged ≥ 18 years who were delivering at one of the selected hospitals and who provided consent during the study period. There were no exclusion criteria. Interventions No interventions were performed. Main outcome measures (1) To test the feasibility of collecting serum at delivery from a large cohort of pregnant women. (2) To test the key operational aspects for a proposed large serocorrelates study. (3) To test the feasibility of collecting samples from those with invasive group B streptococcus. Results A total of 1823 women were recruited during the study period. Overall, 85% of serum samples were collected at three sites collecting only cord blood. At the two sites collecting maternal, cord and infant blood samples, the collection rate was 60%. A total of 614 women were screened for group B streptococcus with a colonisation rate of 22% (serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib, 14% V and 1% IV). A blood sample was collected from 34 infants who were born to colonised women. Maternal and infant blood and the bacterial isolates for 15 newborns who developed invasive group B streptococcal disease during the study period were collected (serotype distribution: 29% III, 29% II, 21% Ia, 7% Ib, 7% IV and 7% V). Limitations Recruitment and sample collection were dependent on the presence of research midwives rather than the whole clinical team. In addition, individualised consent limited the number of women who could be approached each day, and site set-up for the national surveillance study and the limited time period of this feasibility study limited recruitment of all eligible participants. Conclusions We have verified the feasibility of collecting and processing rectovaginal swabs and blood samples in pregnant women, as well as samples from those with invasive group B streptococcal disease. We have made recommendations for the recruitment of cases within the proposed GBS3 study and for controls both within GBS3 and as an extension of this feasibility study. Future work A large case–control study comparing specific immunoglobulin G levels in mothers whose infants develop invasive group B streptococcal disease with those in colonised mothers whose infants do not develop invasive group B streptococcal disease is recommended. Trial registration Current Controlled Trials ISRCTN49326091; IRAS project identification number 246149/REC reference number 18/WM/0147. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 67. See the NIHR Journals Library website for further project information.

Sign in / Sign up

Export Citation Format

Share Document